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Propyl-5-hydroxy-3-methyl-
1-phenyl-1H-pyrazole-4-
carbodithioate (HMPC): a 
new bacteriostatic agent 
against methicillin—resistant 
Staphylococcus aureus
Tatiana Johnston1, Daria Van Tyne2,3, Roy F. Chen1, Nicolas L. Fawzi  4, Bumsup Kwon5, 
Michael J. Kelso  6, Michael S. Gilmore2,3 & Eleftherios Mylonakis1
The emergence of Staphylococcus aureus strains resistant to ‘last resort’ antibiotics compels the 
development of new antimicrobials against this important human pathogen. We found that propyl 
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) shows bacteriostatic activity 
against S. aureus (MIC = 4 μg/ml) and rescues Caenorhabditis elegans from S. aureus infection. Whole-
genome sequencing of S. aureus mutants resistant to the compound, along with screening of a S. aureus 
promoter-lux reporter array, were used to explore possible mechanisms of action. All mutants resistant 
to HMPC acquired missense mutations at distinct codon positions in the global transcriptional regulator 
mgrA, followed by secondary mutations in the phosphatidylglycerol lysyltransferase fmtC/mprF. The 
S. aureus promoter-lux array treated with HMPC displayed a luminescence profile that was unique but 
showed similarity to DNA-damaging agents and/or DNA replication inhibitors. Overall, HMPC is a new 
anti-staphylococcal compound that appears to act via an unknown mechanism linked to the global 
transcriptional regulator MgrA.
Staphylococcus aureus is a highly adaptive human pathogen that is responsible for a variety of diseases ranging 
from soft tissue infections to bacteremia, endocarditis, pneumonia and osteomyelitis1–3. According to a report 
from the US Centers for Diseases Control, the resistance of S. aureus to methicillin and related beta-lactams, as 
well as to cephalosporins poses a large concern for public health. The CDC reported that methicillin-resistant 
S. aureus (MRSA) alone was responsible for 80,461 invasive infections and 11,285 related deaths in 20114. The 
organism possesses a remarkable ability to survive by adapting to changing environmental conditions and by 
mobilizing complex defense mechanisms in response to exogenous stressors5. The overuse of antibiotics in med-
icine and agriculture, together with the use of compounds that target essential cellular functions, such as DNA 
replication, RNA transcription and protein and cell wall synthesis, have put selective pressure on bacteria leading 
to multidrug-resistant strains that are both challenging and expensive to treat6–8. The loss of potency of anti-
biotics to treat S. aureus infections poses a serious threat to public health, as evidenced by the emergence of 
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) strains9–12. The resistance 
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of S. aureus to ‘last resort’ antibiotics (vancomycin, and more recently daptomycin and linezolid) has placed this 
bacterium on the World Health Organization’s list of high priority antibiotic-resistant bacteria for which there is 
an urgent need to develop effective new treatments13.
In this study, we describe the antimicrobial properties of propyl 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-
4-carbodithioate (HMPC) as a new agent against S. aureus and suggest that it likely acts via a novel mechanism 
of action.
Results
Antimicrobial activity. Screening of the Maybridge 5 Library (Maybridge, Thermo Fisher Scientific) iden-
tified HMPC as a compound with direct inhibitory activity against S. aureus MW2 (MIC = 4 μg/ml, Fig. 1A)14 
and the ability to rescue C. elegans from S. aureus MW2 infection15–18, with the fraction of C. elegans survival 
ranging between 93–100% after 5 days of co-incubation (Fig. 1B–D). HMPC appeared to not affect the viability 
of C. elegans at the screening concentration of 7 μg/ml. The compound was found to be equipotent across a panel 
of recent clinical isolates of methicillin-resistant S. aureus from our laboratory collection, where all tested isolates 
had MICs = 4 μg/ml (Table 1).
The spectrum of activity of HMPC was evaluated by determining its MIC against a panel of ESKAPE 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter species) pathogens19,20. In addition to S. aureus, the compound was also found to be 
active against Enterococcus faecium (MIC = 16 μg/ml), but showed no activity against the gram-negative strains 
tested (Table 2). Growth curves of the S. aureus MW2 strain in the presence of increasing concentrations of 
HMPC showed that the compound was able to inhibit growth in a concentration-dependent manner over the 
range 1–4 μg/ml (Fig. 2A). We also performed a time-kill assay using a high concentration of HMPC (16 μg/ml, 
4xMIC) and compared the killing kinetics of HMPC to the rapidly bacteriocidal antibiotic daptomycin (Fig. 2B). 
We found that HMPC did not cause a reduction in bacterial viability until eight hours post-treatment, in contrast 
to the rapidly bacteriocidal nature of treatment with daptomycin.
Screening of a S. aureus promoter-lux clone array. Antibiotic-activated promoter-lux clone arrays 
in S. aureus provide characteristic transcriptional activation light signatures that can be used to discriminate 
between different antibiotic classes based on their mechanism(s) of action21. We screened a promoter-lux array 
to investigate whether HMPC induces transcriptional changes in S. aureus similar to those of known classes of 
antibiotics. HMPC was found to activate promoter-lux clones C, E, F, G, K, L and M (Fig. 3A), which appears to 
be a unique profile but shows some overlap with DNA-damaging agents and/or DNA replication inhibitors21,22.
To test whether HMPC interacts directly with DNA, we first looked for evidence of binding in vitro by exam-
ining the UV visible spectra of HMPC in the absence or presence of excess calf thymus DNA (Fig. S1). No DNA 
hyperchroism or hypochromism was observed, nor were any shifts in positions of absorption bands in the region 
290–360 nm, suggesting that HMPC does not interact with eukaryotic DNA. We confirmed this observation by 
measuring the zones of S. aureus growth inhibition produced by different concentrations of the compound in 
the presence or absence of excess calf thymus DNA (Fig. 3B). The insignificant 3 mm inhibition zone decrease 
was observed in the presence of calf thymus DNA, suggesting that HMPC does not tightly bind to DNA. To test 
whether the compound binds to S. aureus DNA, we conducted disc diffusion assays using varying concentrations 
of HMPC with and without S. aureus MW2 genomic DNA (Fig. 3C). A consistent decrease in the size of the inhi-
bition zone when DNA is included was observed across HMPC concentrations, but the effect was very small and 
was not statistically significant. Finally, we conducted an electrophoretic mobility shift assay (EMSA) on S. aureus 
DNA incubated with HMPC or DMSO solvent alone, which did not show evidence of direct binding (Fig. S2). 
The unique promoter-lux profile produced by HMPC therefore supports it being the prototypical member of a 
new antibiotic class that acts via a novel mechanism. Mesak et al. postulated that new compounds could poten-
tially produce new promoter-lux profiles21 which may apply to HMPC. Additionally, the S. aureus RN4220 strain 
used to created the promoter-lux array possesses mutations that affect the virulence and fitness of the strain, 
which could influence the screening results of novel compounds23.
Isolation and whole-genome sequencing of HMPC-resistant mutants. Single-step resistance selec-
tion, whereby S. aureus MW2 bacteria were plated onto 2x and 4x MIC, produced no HMPC-resistant bacteria 
(data not shown); sequential passaging in liquid medium with increasing concentrations of HMPC, however, 
allowed for the selection of low-level resistant mutants24. Mutant populations with increased MICs of either 8 μg/
ml or 16 μg/ml HMPC were confirmed following several passages in non-selective medium. Three independ-
ent resistance selections were conducted and whole genome sequences were obtained from controls and corre-
sponding mutants with MICs of 8 μg/ml or 16 μg/ml (a total of 9 populations sequenced; Table 3). Analysis of 
high-frequency mutations identified two genes that were repeatedly and independently mutated across multiple 
selections: the transcriptional regulator mgrA (MW0648) and the phosphatidylglycerol lysyltransferase fmtC/
mprF (MW1247). Further analysis of low-frequency mutants in all selected strains revealed additional muta-
tions in both mgrA and fmtC (Table 3). One selected strain also acquired a mutation in a hypothetical protein 
(MW0910) containing a YdiL-like membrane protease domain.
We next tried to understand how the observed mutations might impact the mechanism of HMPC action 
and resistance. The most often mutated gene, mgrA, is a transcriptional regulator that controls the expression 
of a large number of S. aureus genes25,26. The dominant mutations observed all reside within the winged helix 
DNA-binding domain of the MgrA protein (Val55Phe is at the start of α-helix 3, Pro71Gln is at the start of 
α-helix 4 and Arg84His is in a β-strand of the wing region (PDB: 2PV6) (Fig. 4). Two resistant mutants contained 
a single mutation in mgrA, while the remaining strains possessed subpopulations of different mutants, all of 
www.nature.com/scientificreports/
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which are predicted to disrupt protein function (Fig. 4 and Table 3). To test whether MgrA disruption directly 
impacts susceptibility to HMPC, two previously generated S. aureus MW2 mutants lacking a functional mgrA 
(AH3456 and AH4322) were tested for resistance to HMPC27,28. While no difference in MIC was observed in 
either mutant relative to the wild type MW2 strain AH843, both mutants were able to grow to a higher cell density 
at sub-MIC levels of HMPC (Fig. S3).
All three HMPC-resistant populations also developed mutations in the phosphatidylglycerol lysyltrans-
ferase fmtC/mprF (MW1247), and these mutations were correlated with higher resistance to the compound 
(MIC = 16 μg/ml; Table 3). No fmtC deletion mutant exists in the MW2 strain background, but a readily avail-
able fmtC mutant strain was identified in the Nebraska Transposon Mutant Library (NTML, mutant NE1360, 
SAUSA300_1255). The fmtC transposon mutant showed a 2-fold increase in the MIC of HMPC compared to the 
wild type USA300 JE2 strain (MIC = 4 μg/ml; experiments were repeated twice with triplicates or duplicates). 
One resistant mutant also carried a mutation in MW0910, a hypothetical protein that contains a domain similar 
Figure 1. HMPC rescues C. elegans from MRSA infection. (A) Chemical structure of propyl 5-hydroxy-3-
methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC). (B–D) Results of compound screening for C. elegans 
viability following S. aureus MW2 infection. A 384-well assay plate was co-inoculated with C. elegans, S. aureus 
MW2 and either 7 μg/ml HMPC (B); 100% survival), 10 μg/ml vancomycin (C) positive control; 100% survival), 
or 1% DMSO vehicle (D) negative control; 40% survival). Representative Sytox Orange-stained (right) and 
bright field (left) images from assay wells are shown. Only dead worms take up Sytox Orange and fluoresce. 
The images were first captured with an ImageExpress and further processed with CellProfiler to normalize the 
fluorescent or bright field intensity and to define the area of each worm.
www.nature.com/scientificreports/
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to the YdiL membrane protease. The corresponding NTML mutant (NE841, SAUSA300_0932) showed no change 
in MIC compared to the wild type strain (MIC = 4 μg/ml).
The changes that occur in the transcriptional profile of S. aureus upon inactivation or overexpression of MgrA 
are well established26. As a transcriptional regulator, MgrA mediates autolysis in S. aureus29,30. We tested our 
MgrA mutants for autolytic activity and found that the Val55Phe mutant behaved similarly to the wild type strain, 
whereas the Arg84His mutant showed increased sensitivity to treatment with Triton X-100 but was less sensitive 
than the mgrA null mutants (Fig. 5A).
Mammalian cell toxicity assay. As a preliminary assessment of the selectivity of HMPC for bacterial cells 
over mammalian cells, we performed a hemolysis assay with human red blood cells. HMPC showed no hemolytic 
activity over the concentration range tested 0.125–64 μg/ml (Fig. 6A). We also assessed the cytotoxicity of HMPC 
towards HKC-8 kidney cells (Fig. 6B) and found that an approximately 50% reduction in cell viability occurred at 
concentrations close to its MIC against S. aureus MW2. However, HepG2 liver cells were less sensitive to HMPC, 
with 94% survival at 4 μg/ml and then a decrease to an approximately 50% survival at 16 μg/ml (Fig. 6C). A 
detailed structure activity analysis of HMPC by replacing or adding modifications to the structural components 
of the compound and assessing the tradeoffs between toxicity and antimicrobial activity could potentially yield a 
less toxic analog, which could be used as a prototype lead for development of new antimicrobial agents.
Discussion
New antibiotics are urgently needed to combat the growing threat posed by multidrug-resistant strains of S. 
aureus. We identified HMPC, a novel anti-staphylococcal compound in the Maybridge 5 screening library, as 
an antimicrobial agent that inhibited S. aureus growth and rescued C. elegans from MRSA infection15. Here we 
evaluate the mode of action of HMPC, employ a promoter-lux reporter array and whole-genome sequencing of 
S. aureus mutants resistant to HMPC in order to identify possible mechanisms of action, and evaluate the toxicity 
of HMPC to mammalian cells and Galleria mellonella (see Supplementary Fig. S4).
Screening of a S. aureus promoter-lux array with HMPC revealed a unique transcriptional activation profile 
for this compound. The compound activated promoter-lux clones C, E, F, G, K, L and M, a profile that shows some 
overlap with DNA-damaging agents (overlapping activation of C, E, F, K, L, M and non-activation of J) and/or 
DNA replication inhibitors (overlapping activation of C, G, K, L, M and non-activation of J). Because HMPC is 
a compound with previously unknown antibacterial properties with some overlap to DNA-damaging agents, we 
tested whether HMPC can directly bind DNA”. However, we did not observe tight binding to calf thymus DNA 
or genomic DNA from S. aureus MW2 in a UV-visible spectra experiment, disc diffusion assay, or electropho-
retic mobility shift assay. The promoter-lux clones C, E, and to a lesser extent clone F, all of which were activated 
by HMPC, encode recA-lux. We evaluated whether a recA mutant strain might show altered susceptibility to 
HMPC. However, the MIC of HMPC remained unchanged (MIC = 4 μg/ml) against the S. aureus JE2 strain and 
its isogenic mutant lacking a functional RecA protein (NTML, NE805, SAUSA300_1178)31,32. The absence of a 
difference in MIC could further suggest that the SOS response was not due to DNA damage in vivo, but rather 
triggered by a different stressor. It is known, for example, that β-lactam antibiotics trigger SOS responses by com-
promising the integrity of the bacterial membrane, and SOS induction promotes the appearance of mutations 
S. aureus 
strain
HMPC
MIC (µg/ml)
Oxacillin
MIC (µg/ml)a
Vancomycin
MIC (µg/ml)b
BFSA25 4 32 2
BFSA30 4 32 1
BFSA31 4 64 2
BFSA32 4 64 2
BFSA33 4 64 2
BFSA48 4 >64 1
Table 1. Activity of HMPC against methicillin-resistant S. aureus (MRSA) clinical isolates. a,bMIC values for 
oxacillin and vancomycin are shown for comparison.
Pathogen
HMPC, MIC 
(μg/ml)
Vancomycin, 
MIC (μg/ml)
Gentamicin, 
MIC (μg/ml)
Enterococcus faecium E007 16 1–2
Staphylococcus aureus MW2 4 1
Klebsiella pneumoniae WGLW2 >64 0.5
Acinetobacter baumannii ATCC 17978 >64 1
Pseudomonas aeruginosa PA14 >64 2–4
Enterobacter aerogenes Hormaeche and 
Edwards ATCC 13048 >64 1
Table 2. Activity of HMPC against a panel of ESKAPE pathogens. Vancomycin and gentamicin were included 
for comparison purposes.
www.nature.com/scientificreports/
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needed for the development of resistance33. We tested whether sub-MIC concentrations of HMPC increased the 
frequency of spontaneous mutations that give rise to rifampicin resistance, but observed no difference between 
HMPC-treated and untreated bacteria (0.309×1011 untreated versus 0.324×1011 treated). An Ames test also indi-
cated no potential mutagenicity of HMPC (Table S1). Therefore it appears that despite its lux-array profile resem-
bling that of DNA-damaging and SOS-inducing agents, HMPC acts via a distinct mechanism.
Whole-genome sequencing of HMPC-resistant mutants identified two genes that were repeatedly and inde-
pendently mutated in response to HMPC pressure: the transcriptional regulator mgrA (MW0648) and the phos-
phatidylglycerol lysyltransferase fmtC/mprF (MW1247). MgrA is a global transcription regulator that belongs 
to the MarR (multiple antibiotic resistance regulator)/SarA (staphylococcal accessory regulator A) family of 
proteins, which respond to various environmental stressors and play a role in the development of drug resist-
ance8,34–37. MgrA affects the expression of approximately 350 genes that control multiple properties of S. aureus, 
such as expression of virulence factors, regulation of autolysis and antibiotic resistance, as well as other global 
regulatory genes25,26,29,38–40. MgrA also regulates the multidrug-resistance (MDR) efflux pumps NorA, NorB 
and NorC, the non-MDR efflux pump Tet38, and the ABC transporter AbcA in S. aureus. These pumps typi-
cally provide the first line of bacterial defense against antibiotics until more efficient resistance mechanisms can 
emerge41,42. To test whether drug efflux was playing a role in HMPC resistance, we conducted MIC assays in the 
presence of the efflux pump inhibitor thioridazine41,43. The inhibitor was found to have no effect on S. aureus sus-
ceptibility to HMPC with MIC value remaining at 4 μg/ml, suggesting that drug efflux is not a major contributor 
to HMPC resistance.
Figure 2. (A) S. aureus MW2 growth inhibition in the presence of 1–4 μg/ml HMPC. Bacterial culture aliquots 
were periodically taken during log-phase growth to measure the optical density at 600 nm (OD600). Data show 
the mean +/− standard deviation of triplicate values, and significant differences from the control were observed 
for all concentrations tested (p < 0.05 by two-tailed t-test). (B) Killing assay with HMPC or daptomycin (DAP). 
Log-phase cultures were treated with 16 μg/ml of HMPC (4xMIC) or 10 μg/ml DAP and were incubated at 37 °C 
with shaking at 220 rpm. Bacterial survival was monitored after 2, 4, 8, and 24 hours by dilutional plating and 
enumeration of CFU/ml at each time point. The differences between HMPC and DAP are significant at all time 
points except T0 (p < 0.05 by two-tailed t-test).
www.nature.com/scientificreports/
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Clues as to the possible effects of the MgrA mutations that arose in the HMPC-resistant populations could 
be gathered by assessing their location in the crystal structure of the protein44. The Val55Phe and Arg84His var-
iants would clearly introduce steric clashes in the ß-strands near wing 1, a DNA-binding region of the canonical 
winged-helix domain, which cannot be accommodated without changes to the overall protein structure (Fig. 4). 
The Pro71Gln mutation maps to the beginning of DNA-recognition helix 4, which would cause extension of 
the helix and alter the structure of the DNA-binding domain. We predict that the resistance-associated muta-
tions we identified affect the DNA-binding winged-helix domain and thus alter the affinity of MgrA for specific 
DNA-binding sites, leading to transcriptional changes in the resistant bacteria. The precise nature of these expres-
sion changes remains to be explored.
We propose that mutations in MgrA alter the expression of MgrA-regulated genes in response to HMPC, lead-
ing to adaptive responses that affect the susceptibility of S. aureus and allow other, more stable resistance muta-
tions to appear. This hypothesis was supported by the appearance of secondary mutations in fmtC (MW1247) 
during the course of the resistance selection experiment. FmtC, also referred to as multiple peptide resistance fac-
tor (MprF)45, catalyzes the formation of lysyl-phosphatidylglycerol during lipid biosynthesis, a modification that 
Figure 3. Response of the S. aureus promoter-lux array to HMPC treatment. (A) Results of promoter-lux 
array screening. The name of each reporter clone is shown in the upper left corner of each picture. A clear 
zone around the disc indicates inhibition of growth in the presence of higher concentrations of HMPC. At the 
periphery of the inhibition zone, where sub-MIC levels of HMPC are present, changes in luminescence indicate 
altered transcription. The disc on the left is HMPC and on the right of each panel is a DMSO (vehicle) control. 
(B) Zones of S. aureus growth inhibition produced by HMPC in the presence or absence of calf thymus DNA. 
Decreasing quantities of HMPC (25–5 μg) were incubated with either 5 μg calf thymus DNA or TE buffer 
(control) before being spotted onto discs and placed onto agar plates containing S. aureus MW2 bacterial lawns. 
(C) Disc diffusion assay with varying concentrations of HMPC in the absence or presence of S. aureus genomic 
DNA. HMPC was incubated without or with 5 μg of S. aureus genomic DNA and was then applied to a filter 
paper disc and placed onto a TSA plate containing S. aureus MW2 bacteria in a soft agar overlay. After overnight 
incubation at 37 °C, zones of inhibition were measured with a ruler. Bars show mean values +/− standard 
deviation of three independent assays, and no differences are statistically significant.
www.nature.com/scientificreports/
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Selection MIC (μg/ml) MW2 pos (bp) Typea Length (bp) Gene ID Frequency (%) Protein changeb
1 8 731157 MNV 17 MgrA 46.8 G108fs
731244 SNV 1 MgrA 51.9 R84H
2 8 731332 SNV 1 MgrA 100 V55F
3 8 731158 Deletion 12 MgrA 52.9 L109del4
731283 SNV 1 MgrA 28.9 P71N
731470 SNV 1 MgrA 10.5 E9*
1 16 731244 SNV 1 MgrA 100 R84H
1366975 Deletion 4 FmtC 93.5 I461fs
2 16 731295 SNV 1 MgrA 20.9 G67A
731332 SNV 1 MgrA 77.4 V55F
1366139 Deletion 7 FmtC 28 I181fs
3 16 731283 SNV 1 MgrA 100 P71N
1005808 Insertion 1 Hyp YdiL 85 L151fs
1366760 Deletion 684 FmtC 100 N386del228
Table 3. Mutations identified in HMPC-resistant S. aureus mutants selected in vitro. aMNV = Multi-nucleotide 
variant; SNV = Single Nucleotide Variant. bfs = frame-shift; *stop codon.
Figure 4. HMPC resistance-associated mutations in MgrA map to the DNA-binding domain. The MgrA dimer 
(PDB: 2BV6) is shown with the two equivalent subunits colored light blue and white/grey. Missense variants at 
Val55, Pro71, and Arg84 (shown in red) are all found in the winged-helix DNA-binding domain (left, bottom 
half), including in the DNA recognition helix. Image created in PyMOL with Flaticon.
Figure 5. Autolysis assay for HMPC-resistant mutants containing Val55Phe and Arg84His mutations in MgrA. 
Bacteria were grown in a 96-well plate at 37 °C without shaking and optical density at 600 nm (OD600) was 
measured hourly. The strains AH843, AH3456, and AH3422 were included as controls. The experiment was 
repeated twice with triplicates for each strain. Data show the mean +/− standard deviation, and p < 0.001 by 
one-way RM ANOVA 5 followed by Student-Newman-Keuls method.
www.nature.com/scientificreports/
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increases cell surface positive charge and confers protection against cationic antibiotics46–50. It has been suggested 
that MprF plays a biophysical role in membrane stability and organization, and that this can modify S. aureus 
susceptibility to antibiotics47,51. A change in membrane organization that reduces HMPC entry into bacterial cells 
would explain the increased resistance we observed in the S. aureus JE2 fmtC mutant strain. In conclusion, neither 
of the resistance-associated genes we identified is likely to be the cellular target of HMPC. Thus further studies are 
needed to determine the precise mechanism of action of this compound.
Overall, we report a novel bacteriostatic agent that effectively inhibits the growth of drug-resistant S. aureus. 
While the mechanism of action of HMPC remains unknown, we postulate that it acts on multiple targets within 
the bacterial cell to induce a stress response, which can be mitigated by transcription changes driven by mutations 
in MgrA. These changes are followed by a rise in more specific mutations that affect the cellular membrane and 
possibly reduce entry of HMPC into S. aureus cells. Future work will focus on the synthesis of structural analogs 
that retain anti-staphylococcal activity but are less toxic to mammalian cells.
Figure 6. Mammalian cell toxicity assays. (A) HMPC hemolysis assay. Red blood cells were diluted to 2% with 
PBS and then incubated with HMPC over the concentration range 0.125−64 μg/ml. (B) Cytotoxicity of HMPC 
towards HKC-8 cells. HKC-8 cells were treated with increasing concentrations of HMPC for 24 hours before 
assessing viability using a WST-1 assay. (C) Cytotoxicity of HMPC towards HepG2 cells. HepG2 cells were 
treated with increasing concentrations of HMPC for 24 hours before assessing viability using a WST-1 assay. All 
experiments were repeated twice in triplicate and data show the mean +/− standard deviation.
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Materials and Methods
Bacterial strains and media. The bacterial strains used in this study are listed in Table 4. Bacterial cultures 
were grown either in Mueller-Hinton Broth (MHB) (212322, BD Biosciences, MD, USA) or Bacto Tryptic Soy 
Broth (TSB) (21825, BD Biosciences, MD, USA) liquid medium or on solid agar plates (05040, Agar powder for 
microbiology, Sigma-Aldrich, MO, USA). The growth of bacterial clones and screening of the S. aureus promot-
er-lux array were performed using NYE medium supplemented with 10 μg/ml chloramphenicol (NYEC)52.
Minimum inhibitory concentration, dose response, and antimicrobial killing assays. Propyl 
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) was purchased from Fisher HealthCare 
(Thermo Fisher Scientific, TX, USA). The compound was dissolved in 100% DMSO at a concentration of 5 mg/
ml. The MIC was determined by a two-fold broth microdilution procedure in 96-well plates in MHB according 
to standard methods53. Dose-response curves were generated by measuring optical density (OD600) of the MIC 
plate after 24 hours of growth using a Synergy plate reader and Gen5 software (Biotek Instruments, VT, USA). 
For antimicrobial killing assays, log-phase cultures (OD600 = 0.3) grown in MHB were treated with 16 μg/ml of 
HMPC (4xMIC) or 10 μg/ml daptomycin and were incubated at 37 °C with shaking at 220 rpm. Bacterial survival 
was monitored after 2, 4, 8, and 24 hours by dilutional plating and enumeration of CFU/ml at each time point.
Growth inhibition of S. aureus MW2 by HMPC. An overnight culture of S. aureus MW2 was diluted 
into MHB containing HMPC at varying concentrations and the bacteria were grown at 37 °C for 24 hours. DMSO 
was used as vehicle control. Bacterial culture aliquots were periodically drawn to measure the optical density at 
600 nm (OD600) on an Eppendorf BioPhotometer Plus (Eppendorf of North America, NY, USA).
Screening of S. aureus promoter-lux reporters. Screening of S. aureus promoter-lux clones was per-
formed according to the published protocol21. In brief, a single colony of each luminescent S. aureus clone was 
re-suspended in sterile water, diluted 1000-fold into 0.7% (w/v) agar and spread evenly across the surface of 
NYEC plates. Paper discs (232189, BD Biosciences, NJ, USA) containing 2 μg of HMPC were placed onto the 
plates and incubated at 37 °C for 20 h. Discs containing DMSO were added to plates as controls. Luminescence 
was detected with an IVIS Lumina III In Vivo Imaging System (Perkin Elmer, MA, USA).
Assessment of HMPC binding to DNA. To assess HMPC binding to eukaryotic DNA, UV-visible spectra 
were recorded on a Beckman DU 80 spectrophotometer54 using a quartz micro cell cuvette. Measurements were 
obtained for calf thymus DNA in Tris—HCl buffer (pH 7.2, 10 mM) in the presence or absence of HMPC (20 μg/
ml) over the wavelength range of 290–400 nm (10 nm increments), as described previously54. We also assessed 
the effect of DNA on the zone of growth inhibition of S. aureus produced by HMPC using calf thymus DNA and 
genomic DNA from S. aureus MW2. The experiment with calf thymus DNA was performed as described previ-
ously55 with minor modifications. Solutions of HMPC (5 μg-25 μg) were mixed with 5 μg calf thymus DNA and 
incubated for 10 min at RT before being spotted onto discs (232189, BD Biosciences, NJ, USA) and overlaid onto 
S. aureus MW2 lawns growing on MHA medium. The zones of growth inhibition were visually observed and 
measured with a ruler after incubation at 37 °C for 21 h. Experiments were performed twice.
To assess HMPC binding to prokaryotic DNA, solutions containing 10–25 μg of HMPC were left untreated or 
were mixed with 5 μg S. aureus MW2 genomic DNA. Solutions were then spotted onto filter paper discs and over-
laid onto a TSA plate containing MW2 bacteria in a soft agar overlay. After overnight incubation at 37 °C, zones 
of inhibition were measured with a ruler. Finally, an electrophoretic mobility shift assay (EMSA) was conducted 
by incubating S. aureus MW2 genomic DNA (500 ng) with DMSO alone or with 5 μg HMPC dissolved in DMSO, 
and then running the mixtures on a 1% agarose gel at 70 volts for 4 hours. The gel was then stained with 0.5 μg/ml 
ethidium bromide to visualize the DNA bands.
Species Strain name
Staphylococcus aureus, MRSA MW2 (laboratory collection)
Staphylococcus aureus,MRSA AH843, MW2 (Horswill laboratory)
Staphylococcus aureus, MRSA USA300 JE2 (Department of Pathology and Microbiology, University of Nebraska)
Staphylococcus aureus JE2 mutants Nebraska Transposon Mutant Library (BEI Resources)
Staphylococcus aureus,MRSA AH3456, MW2 ∆mgrA::tetM (Horswill laboratory)
Staphylococcus aureus,MRSA AH3422, MW2 ∆mgrA (Horswill laboratory)
Staphylococcus aureus MgrA mutant MW2, R84H mutation in MgrA
Staphylococcus aureus MgrA mutant MW2, V55H mutation in MgrA
Enterococcus faecium E00760
Klebsiella pneumoniae WGLW2 (HM-751, BEI Resources)
Acinetobacter baumannii ATCC 17978
Enterobacter aerogenes Hormaeche and Edwards ATCC 13048
Pseudomonas aeruginosa PA1461
Staphylococcus aureusclinical isolates, MRSA BFSA25, BFSA30, BFSA31, BFSA32, BFSA33, BFSA48, BFSA49, BFSA50, BFSA51 (Mylonakis laboratory collection)
Table 4. Bacterial strains used in this study.
www.nature.com/scientificreports/
1 0SCIENtIfIC RepoRTs |  (2018) 8:7062  | DOI:10.1038/s41598-018-25571-w
Determination of the frequency of rifampicin-resistant mutants. An overnight culture of S. aureus 
MW2 was diluted to the McFarland standard 0.5 in TSB medium and grown until mid-log phase. Bacteria were 
serially diluted 10-fold in TSB medium and aliquots were plated on either rifampicin-containing TSA plates, to 
determine the number of resistant mutants, or non-selective plates, to determine the number of CFU/ml. The 
mutation frequency was calculated as the ratio of rifampicin-resistant mutants to total cells in the population, as 
described previously56,57.
Selection of HMPC-resistant S. aureus MW2 mutants. Sequential passaging in liquid medium to 
develop HMPC-resistant isolates was performed as previously described24. For the first round of selection, an 
overnight culture of S. aureus MW2 was diluted to an optical density at 600 nm (OD600) of 0.1 in TSB medium 
supplemented with 1xMIC, 2xMIC, and 4xMIC HMPC (in triplicate). After 24 h of incubation at 37 °C with 
shaking at 200 rpm, the tube with the highest HMPC concentration that contained visible bacterial growth 
(OD600 > 0.1) was used to dilute the bacterial culture to OD600 = 0.1 for the next round of selection, and to deter-
mine the concentrations of HMPC to be tested. The MIC of cultures derived from strains grown in the highest 
HMPC concentration was used to confirm resistance to the compound.
Whole genome sequencing and variant calling. Genomic DNA from overnight cultures of S. aureus 
MW2 control and resistant strains was isolated using a DNeasy Blood and Tissue kit (Qiagen, CA, USA) using the 
manufacturer’s protocol. A paired-end sequencing library (2x250 bp) was prepared for each DNA sample using a 
Nextera XT kit (Illumina, CA, USA). Libraries were pooled and sequenced using an Illumina HiSeq. 2500 (MEEI 
Ocular Genomics Institute, Boston, MA). Variants were identified using Pilon58, by mapping sequencing reads 
to the closed S. aureus MW2 genome (GenBank accession GCA_001019125.1). Unique variants found in the 
selected strains that were absent in control strains are reported. Additional low-frequency mutations in mgrA and 
fmtC were identified using CLC Genomics Workbench version 7.0 (CLC bio, MA, USA).
Minimum inhibitory concentration of HMPC in the presence of an efflux pump inhibitor. The 
effect of the efflux pump inhibitor thioridazine on S. aureus MW2 susceptibility to HMPC was evaluated using 
the 2-fold microdilution method in the presence of a sub-inhibitory concentrations of thioridazine (0.5 μg/ml), 
as previously described41.
Triton X-100 – induced autolysis assay under static conditions. Overnight cultures of S. aureus 
strains were diluted to an optical density at 600 nm (OD600) of 0.1 in TSB with 0.05% Triton X-100. Cells were 
incubated in 96-well plates at 37 °C without shaking, and optical densities were recorded hourly for 8 hours.
Mammalian cell cytotoxicity assay. Growth media and other cell culture reagents were obtained from 
Thermo Fisher Scientific. HKC-8 immortalized human renal proximal tubular epithelial cells were maintained in 
Dulbecco’s Modified Eagle Medium/Nutrient F-12 Ham (DMEM/F12) supplemented with 10% FBS. The HepG2 
liver cells were from ATCC (HB-8065) and cells were grown in Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% FBS. HKC-8 and HepG2 cells were cultured in 96 - well tissue culture plates at a density 
of 10000 cells/well, followed by the addition of HMPC in various concentrations or control medium (DMEM/
F12 or EMEM with 0.01% DMSO). The cells were subsequently incubated for 24 hours prior to the application of 
Cell Proliferation Reagent WST-1 (WST-1 reagent Roche, IN, USA), according to the manufacturer’s instructions. 
Each concentration of HMPC was tested in triplicates and the experiment was repeated twice.
Hemolysis assay. Human erythrocytes were purchased from Rockland Immunochemicals (Human red 
blood cells 10% washed pooled cells, R407-0050). The assay was performed as described59 in triplicates and 
repeated twice.
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